Crystal Kennedy, NP
Primary Care · Auburn, INNPI 1902267057
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 55 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by Novo Nordisk at 27.6% of the total.
Across 55 payments — averaging $24.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$368
- AstraZeneca$159
- Axsome Therapeutics, Inc.$143
- AbbVie$105
- GSK$100
- Lilly USA, LLC$56
- plus $399 from 16 others
What the payments were for
- Food & beverage$1,330100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 11 | $368 |
| AstraZeneca | 3 | $159 |
| Axsome Therapeutics, Inc. | 2 | $143 |
| AbbVie | 7 | $105 |
| GSK | 7 | $100 |
| Lilly USA, LLC | 3 | $56 |
| Amgen | 3 | $53 |
| Exact Sciences | 2 | $47 |
| Kowa Pharmaceuticals America, Inc. | 2 | $39 |
| Nestle Healthcare Nutrition Inc. | 2 | $30 |
| Boehringer Ingelheim | 2 | $29 |
| Pfizer | 1 | $26 |
| Viiv Healthcare Company | 1 | $24 |
| Abbott | 1 | $24 |
| Biomerieux Inc | 1 | $21 |
| Amarin Pharma, Inc. | 1 | $20 |
| Novartis | 1 | $17 |
| Daiichi Sankyo Inc. | 1 | $16 |
| Astellas Pharma US Inc | 1 | $15 |
| Adlon Therapeutics L.p. | 1 | $14 |
| Merck | 1 | $13 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$1,330 in reported general payments places this provider in the 80th percentile of 113 primary care providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 18 | $23,571 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 31 | $276 |
| Methylprednisolone | 37 | $258 |
| Cephalexin | 22 | $257 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 12 | $235 |
| Doxycycline Monohydrate | 12 | $146 |
| Levothyroxine Sodium | 11 | $127 |
| Losartan Potassium | 12 | $96 |
| Prednisone | 38 | $72 |
| Atorvastatin Calcium | 15 | $47 |
| Azithromycin | 13 | $37 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $368 | $23,57118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 113 primary care providers in Indiana.
Other primary care in Auburn
- Katrina MotleyIndianapolis$18K
- Stephanie BodamerBloomington$6K
- Candace KapranosGary$5K
- Jalyn GoolsbyNew Albany$4K
- Ashley VirtMuncie$4K
- Lana HumeCarmel$3K
- Illia LeiberingTell City$3K
- Jiyoung ChaeWest Lafayette$3K
- Leigha Bowyer-JonesJeffersonville$3K
- Heather PickettNoblesville$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.